{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-000368","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2023-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.598978+00:00","generated_at":"2026-06-20T20:13:58.757480+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Palisade Bio closes $2.5M registered direct offering and concurrent private placement","bullets":["Raised approximately $2.5M gross via 1,052,631 shares/pre-funded warrants at $2.375/share plus 1,052,631 five-year warrants at $2.375.","Transaction closed January 4, 2023; Ladenburg Thalmann acted as exclusive placement agent.","Proceeds intended for working capital and general corporate purposes.","Offering includes registered direct (513,842 shares/pre-funded warrants) and unregistered private placement (538,789 pre-funded warrants).","Company agreed to file resale registration statement for underlying shares within 30 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-000368","json":"https://secwatch.observer/filing/0001493152-23-000368.json","markdown":"https://secwatch.observer/filing/0001493152-23-000368.md","text":"https://secwatch.observer/filing/0001493152-23-000368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/0001493152-23-000368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:13:58.757480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a08e3a0d16c97ad85d2fc2a2298ccfc512204dd7","claim":"PALISADE BIO, INC. entered into Purchase Agreements with certain institutional and accredited investors valued at approximately $2.5 million (effective 2022-12-30).","evidence_excerpt":"On December 30, 2022, Palisade Bio, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 476,842 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a purchase price per share of $2.375, and (ii) registered prefunded warrants (the “Registered Prefunded Warrants”) to purchase up to 37,000 shares of Common Stock at a purchase price of $2.3749 per Registered Prefunded Warrant (the “Registered Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223000368/0001493152-23-000368-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"approximately $2.5 million"},{"label":"Effective","value":"2022-12-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}